KEROS THERAPEUTICS IN

Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference

07 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition

12 Dec 2022 09:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

22 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions

07 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047

03 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

03 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

12 Sep 2022 05:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the American Society for Bone and Mineral Research 2022 Annual Meeting

06 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

06 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

04 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

13 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association

10 Jun 2022 05:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

18 May 2022 05:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

17 May 2022 15:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association

12 May 2022 15:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports First Quarter 2022 Financial Results

05 May 2022 07:00:03 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

09 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer

31 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

13 Dec 2021 15:05:00 By Nasdaq GlobeNewswire